Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.42 |
| ▸ | GFER | P55789 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122248 | 0.95 | CHRNB4 (0.46) | ARCHRNB4CHRNA3GFERCHRNB2 | |
| SCHEMBL13681594 | 0.95 | CHRNB4 (0.46) | ARCHRNB4CHRNA3GFERCHRNB2 | |
| SCHEMBL2789738 | 0.95 | CHRNB4 (0.46) | ARCHRNB4CHRNA3GFERCHRNB2 | |
| Hydrochloric Acid SCHEMBL2789827 | 0.94 | CHRNB4 (0.45) | ARCHRNB4CHRNA3GFERCHRNB2 | |
| SCHEMBL2792598 | 0.87 | GFER (0.39) | ARCHRNB4CHRNA3GFERCHRNB2 | |
| SCHEMBL2791991 | 0.84 | CASP1 (0.44) | ARCHRNB4CHRNA3GFERCHRNB2 | |
| SCHEMBL2791769 | 0.83 | AR (0.37) | ARCHRNB4CHRNA3GFERCHRNB2 | |
| SCHEMBL2792586 | 0.83 | CHRNB4 (0.40) | ARCHRNB4CHRNA3GFERCHRNB2 | |
| SCHEMBL2790790 | 0.82 | GFER (0.36) | ARCHRNB4CHRNA3GFERCHRNB2 | |
| SCHEMBL24565301 | 0.82 | AR (0.45) | ARMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021043152-A1 | PYRIMIDINE DERIVATIVE AS WEE1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2021-03-11 | — | — | WO | disclosed |
| WO-2010034626-A2 | NOVEL DEVELOPER COMPONENTS | HENKEL AG & CO. KGAA (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034626-A2 | NOVEL DEVELOPER COMPONENTS | HENKEL AG & CO. KGAA (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1212330-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20030186970-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC, | 2003-10-02 | — | — | US | disclosed |
| US-6462038-B1 | SUCH AS 1,2,3,6-TETRAHYDRO-1-METHYL-9-(TRIFLUOROMETHYL)-7H-(1,4)OXAZINO(3,2 -G)QUINOLIN-7-ONE; NONSTEROIDAL, HIGH AFFINITY AND SPECIFICITY ANTAGONISTS AND AGONISTS OR PARTIAL AGONISTS, I.E. PARTIAL AND/OR TISSUE SPECIFIC ACTIVATORS | LIGAND PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| WO-2001016139-A9 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-1212330-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016139-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186970-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885CHRNB4 544/4885CHRNA3 524/4885 |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885CHRNB4 544/4885CHRNA3 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.